MedTrace Logo

Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

NCT01479296 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-10-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the immune response to the Vaccine Research Center (VRC) rAd5 HIV vaccine when the vaccine components are administered in three different ways, in healthy, HIV-uninfected adults.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C)

Given intramuscularly

BIOLOGICAL

rAd5 env A

Given intramuscularly

BIOLOGICAL

rAd5 env B

Given intramuscularly

BIOLOGICAL

rAd5 env C

Given intramuscularly

BIOLOGICAL

rAd5 gag-pol

Given intramuscularly

BIOLOGICAL

Placebo Vaccine

Given intramuscularly

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Ian Frank · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-05-31
Completion
2017-11-27

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01479296 on ClinicalTrials.gov